Where there are problems with respect to the availability of authorised auxiliary medicinal products, unauthorised auxiliary medicinal products may be used in a clinical trial in justified cases. The price of the authorised auxiliary medicinal product should not be considered as having an effect on the availability of such medicinal products.
Recital 53, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…
In forcesince 16 Apr 2014